drugset / Trial / NCT04536077
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Phase 2
Terminated
16 enrolled
Washington University School of Medicine
Celldex Therapeutics · collabNational Cancer Institute (NCI) · collabThe Foundation for Barnes-Jewish Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
Timeline
- Start
- 2021-08-13
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-1140 | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | CDX-301 | Protein / enzyme biologic | 75 ug/kg | Subcutaneous |